<DOC>
	<DOCNO>NCT01479361</DOCNO>
	<brief_summary>Background : - People infected human immunodeficiency virus ( HIV ) risk get certain disease . Two disease type pneumonia know PCP brain infection call toxoplasmosis . Most people HIV take antiretroviral ( ARV ) drug treat HIV low risk infection . However , ARV drug may make drug use treat PCP toxoplasmosis less effective . Researchers want test specific ARV drug see affect atovaquone , drug use treat PCP toxoplasmosis . Objectives : - To see ARV drug atazanavir-ritonavir efavirenz low blood level atovaquone . Eligibility : - Individuals 18 70 year age HIV . - Participants must take efavirenz atazanavir-ritonavir , take ARV drug . Design : - Participants screen physical exam medical history . They also blood urine test . - This study screen visit five study visit . Two study visit last 12 hour ; three visit last 1 hour . - Participants receive either low dose high dose atovaquone take 14 day . They record dose symptom diary card home . - After 14 day , participant 12-hour visit provide blood sample . There wash-out period dose 6 week . - After wash-out period , participant switch dose level either high low dose . - After 14 day , participant 12-hour visit provide blood sample .</brief_summary>
	<brief_title>Antiretroviral Drug Interaction Study Volunteers With HIV</brief_title>
	<detailed_description>The incidence opportunistic infection Pneumocystis jirovecii pneumonia ( PCP ) Toxoplasma gondii substantially decline patient HIV infection due potent combination antiretroviral ( ARV ) therapy effective prophylaxis . The drug choice prophylaxis treatment PCP toxoplasmosis trimethoprim-sulfamethoxazole ( TMP-SMX ) sulfadiazine , respectively . In patient tolerate first line therapy , atovaquone common alternative . While generally consider safe effective , recent drug interaction study involve single dose combination tablet atovaquone/proguanil ( Malarone ) HIV-infected patient show atovaquone plasma concentration significantly lower ( compare healthy volunteer ) 75 % , 74 % , 46 % patient take ARV medication efavirenz ( EFV ) , lopinavir-ritonavir ( LPV/r ) , atazanavir-ritonavir ( ATV/r ) , respectively . The mechanism drug interaction unknown presumably due induction uridine diphosphate glucuronsosyltransferase ( UGT ) enzymes responsible metabolism atovaquone . The magnitude interaction strongly suggest clinically relevant drug interaction atovaquone aforementioned ARVs . The purpose study determine whether HIV-infected subject receive ATV/r EFV-containing ARV regimens , experience reduction atovaquone exposure steady state condition compare HIV-infected patient receive ARV therapy . In open-label study , 30 HIV-infected subject participate 1 3 group 10 ( Groups A , B , C ) . Group A consist 10 subject already receive combination ARV therapy contain ATV/r ; Group B consist 10 subject already receive combination ARV therapy contain EFV ; Group C consist 10 subject currently receive ARV therapy . All subject Groups A , B , C randomly assign either receive atovaquone 750 mg twice daily 14 day ( Phase 1 ) follow 2-6 week washout period , follow atovaquone 1500 mg twice daily 14 day ( Phase 2 ) , vice versa . Pharmacokinetic ( PK ) sample atovaquone occur Day 14 Phase 1 2 . Atovaquone PK parameter determine use non-compartmental method WinNonlin professional computer program ( version 5.2 ; Pharsight Corporation , Mountain View , CA ) . The following PK parameter compare among group : area concentration vs. time curve ( AUC ? ) , maximum concentration ( Cmax ) , apparent oral clearance ( Cl/F ) , time reach maximum concentration ( Tmax ) , half-life ( T ( Omega ) ) . Data investigation determine whether ATV/r and/or EFV alter steady state PK atovaquone HIV-infected subject . This information assist clinician choose appropriate alternative therapy treatment PCP toxoplasmosis patient candidate first line therapy .</detailed_description>
	<mesh_term>Toxoplasmosis</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<criteria>INCLUSION CRITERIA : A subject consider eligible study follow criterion meet : 1 . Between age 18 70 year . 2 . HIVinfected patient stabilize ( great equal 90 day ) ARV regimen contain efavirenz 600 mg daily , atazanavir/ritonavir 300/100 mg daily HIVinfected patient receive ARV therapy . 3 . CD4 cell great equal 350 cells/mm3 HIVinfected patient receive ARV therapy . 4 . CD4 cell &gt; 200 cells/mm3 HIVinfected patient receive ARV therapy . 5 . Virologically suppressed patient receive ARV therapy ( &lt; 200 copies/mL least 2 consecutive occasion , within 6 month prior enrollment ) . 6 . Females child bear potential able willing prevent pregnancy ( ) practice abstinence ( b ) use effective method birth control , condom , study period 1 month study completion . 7 . Subject agree storage specimens future research . EXCLUSION CRITERIA : A subject ineligible study 1 follow criterion meet : 1 . Concomitant routine therapy prescription , overthe counter , herbal , holistic medication know suspected alter atovaquone include rifampin , rifabutin , metoclopramide 14 day prior study participation . 2 . Subjects receive primary secondary prophylaxis PCP toxoplasmosis . 3 . ARV regimens contain EFV ATV/r . 4 . Subjects receive hormonal contraceptive within 90 day Study Day 1 . 5 . Inability obtain venous access sample collection . 6 . Laboratory and/or physical evidence active opportunistic infection . Diabetes mellitus require treatment insulin , active tuberculosis , cardiac disease ( uncontrolled hypertension and/or heart failure etc . ) , renal disease ( chronic acute renal failure insufficiency result baseline serum creatinine great 1.5 time upper limit normal [ ULN ] ) , untreated/uncontrolled thyroid disease , untreated/uncontrolled psychiatric disease , active hepatitis ( liver failure result liver function test great 3 time ULN , ascites , jaundice absence ATV ) , condition may interfere interpretation study result best interest subject opinion Investigator . 7 . Positive pregnancy test breastfeed female . 8 . The presence persistent diarrhea malabsorption could interfere subject ability absorb drug . 9 . Drug alcohol use may impair safety adherence . 10 . History intolerance allergic reaction ( rash ; hive ; swell lip ; difficulty breathe ) atovaquone . 11 . Bleeding disorder ( hemophilia , G.I. , intracranial bleeding ) . 12 . Organ transplant recipient . 13 . Documented ongoing problem medication adherence . 14 . High likelihood switch ARV regimen within 12 week start study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 1, 2016</verification_date>
	<keyword>Atovaquone</keyword>
	<keyword>Drug Interaction</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Atazanavir-Ritonavir</keyword>
	<keyword>HIV</keyword>
</DOC>